Jazz Pharmaceuticals plc
JAZZ
$125.22
-$0.94-0.75%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 16.47% | -17.49% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 16.47% | -17.49% | |||
| Cost of Revenue | 55.56% | -17.79% | |||
| Gross Profit | 12.92% | -17.46% | |||
| SG&A Expenses | -30.27% | 28.59% | |||
| Depreciation & Amortization | 4.96% | -2.80% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.51% | 7.47% | |||
| Operating Income | 941.80% | -111.38% | |||
| Income Before Tax | -566.62% | -182.85% | |||
| Income Tax Expenses | 3.60% | 69.24% | |||
| Earnings from Continuing Operations | -676.38% | -148.42% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -676.38% | -148.42% | |||
| EBIT | 941.80% | -111.38% | |||
| EBITDA | 183.00% | -65.02% | |||
| EPS Basic | -673.65% | -148.07% | |||
| Normalized Basic EPS | 310.16% | -146.72% | |||
| EPS Diluted | -673.65% | -148.84% | |||
| Normalized Diluted EPS | 310.16% | -147.47% | |||
| Average Basic Shares Outstanding | 0.35% | 0.73% | |||
| Average Diluted Shares Outstanding | 0.35% | -0.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||